๐๏ธ Verified NIH Record โข Updated 2025-12-03
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment (NCT02932280)
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
๐ต Active, Not Recruiting Phase1 / Phase2 ๐ Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Who can join: Review the eligibility criteria below.
Location: Phoenix Children'S Hospital โ Phoenix, Arizona
Age range: 3 Years to 21 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (9 Sites)
- Phoenix Children'S Hospital โ Phoenix, Arizona
- Arkansas Children's Hospital โ Little Rock, Arkansas
- Stanford University School of Medicine and Stanford Cancer Institute โ Palo Alto, California
- Arnold Palmer Hospital for Children โ Orlando, Florida
- Memorial Sloan Kettering Cancer Center โ New York, New York
- Pennsylvania State Hershey Children's Hospital โ Hershey, Pennsylvania
- University of Texas โ San Antonio, Texas
- Huntsman Cancer Institue โ Salt Lake City, Utah
- Alberta Children'S Hospital โ Calgary, Alberta
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors โ Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer โ Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer โ Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors โ Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors โ New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation โ New York, New York
Explore by condition: All Solid Tumor clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.